Skip to main content


Fig. 2 | Arthritis Research & Therapy

Fig. 2

From: Systematic review and meta-analysis of serious infections with tofacitinib and biologic disease-modifying antirheumatic drug treatment in rheumatoid arthritis clinical trials

Fig. 2

Incidence rates for serious infections with biologic DMARDs and tofacitinib across RCTs* and LTE studies. The results displayed did not include the continuity factor to account for zero incidence rates due to the low percentage of zero incidence rates for serious infections within these trials (<10 %). Tofacitinib data as of April 2013. *Clinical trial data published between 1999 and 2013. BID twice daily, CI confidence interval, DMARD disease-modifying antirheumatic drug, LTE long-term extension, pt-yrs patient-years, RCT randomized controlled trial, TNFi tumor necrosis factor inhibitors

Back to article page